Fibrosis is a common terminal state of many chronic diseases and there
are few effective treatments at present. The gliptin is a class of DPP4
inhibitors used in the treatment of type 2 diabetes. At present, many
studies show that it may have the effect of inhibiting fibrosis. In
order to explore the role of the gliptin in different fibrotic diseases,
we searched the related literature about the fibrotic diseases and the
gliptin. In our review, we found that the gliptin can inhibit the
fibrotic process through a variety of mechanisms. The evidence for the
inhibition of atherosclerosis by the gliptin is strong. For pulmonary,
renal and cardiac fibrosis, more clinical studies are needed to support
it. However, there is no benefit in the treatment of liver fibrosis with
the gliptin. To sum up, it is true that the gliptin has the
broad-spectrum anti-fibrotic effects.